Drug
Fruquintinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | VEGFR targeting TKI |
| Mechanism of Action | VEGFR1/2/3 inhibitor |
| Half-life | 42 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing chiefly via vascular normalization/endothelial killing; dose-dependent (Jiang et al., Cancer Medicine, 2023; Guelfi et al., Nature Reviews Cancer, 2024). As with other antiangiogenics, endothelial adverse effects are not tumor-restricted, providing a rationale for increased vascular normal-tissue injury (GI perforation/fistula, mucosal injury, and possible cerebral radionecrosis), especially at higher doses.
Data on this page refer exclusively to patients treated with
Fruquintinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
VEGFR targeting TKI group page.